Actinic Keratosis Market | Top Players are Tolmar Pharmaceuticals Inc., DUSA Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., etc

According to the latest report published by Acute Market Reports, Inc., the market for actinic keratosis was valued at USD 6.561.8 million in 2015 and is expected to reach USD 8.909.7 million by 2022, with the market growing at CAGR 4.35 per cent from 2016-2022.

Market Insights

Actinic keratosis (AK) is characterized by skin papules, macules or plaques resulting from prolonged exposure to harmful UV and may result in squamous cell carcinoma. The risk of developing actinic keratosis increases with increasing age and is particularly higher in both men and women. Approximately 5-20 percent of patients with actinic keratosis develop malignant and potentially fatal squamous cell carcinomas.

Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/actinic-keratosis-market

Destructive therapies such as liquid nitrogen cryotherapy and surgical therapy are the gold standard for AK therapy among the various treatment methods available. Cryotherapy was the most commonly sought treatment by clinicians in 2015. However, improved clinical results of photodynamic therapy and a growing preference for drug-device combination therapy have encouraged both caregivers and patients to opt for novel treatment methods that offer both advanced efficacy, esthetic benefits and reduced risk of future malignancies. Topical treatment is a prolonged treatment and is comparatively more effective than other treatments, but patient compliance is a key issue that hinders the growth of this segment. Photodynamic therapy is the fastest growing treatment during the forecast period due to an increasing demand for non-invasive surgery, and fewer treatment sessions are the key factors expected to help this market.

North America is the largest market for actinic keratosis treatment due to growing prevalence of AK, better public awareness about occurrence of AK and associated risk of squamous cell carcinoma. According to American Academy of Dermatology (AAD), approximately 60% of the Americans aged 40 year or above, Actinic Keratosis is predisposed to develop having at least 1 AK lesion. Actinic keratosis is precursors of squamous cell cancer. U.S. held the largest share in the actinic keratosis market in 2015 owing to current prevalence of actinic keratosis in the region.Asia Pacific is the fastest growing market for AK treatments. Australia has the highest prevalence of actinic keratosis ranging between 40% to 60% in adult population. Growing awareness in the region and rapid development in healthcare infrastructure and healthcare expenditure are the key growth factors in Asia Pacific actinic keratosis market.

This market is majorly driven by wide presence of generic drugs and is moderately competitive. Photodynamic therapy market has developed a niche with methyl aminolevulinate and aminolevulinic acid drugs. Galderma and DUSA pharmaceuticals are the chief players in this space.

Some of the major players in the global actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others.

Report Scope by Segments

By Treatment Type

• Destructive  Treatment
  • Liquid Nitrogen Cryotherap
  • Surgical Therapy
• Photodynamic Therapy
  • 5-aminolevulinic acid (ALA)
  • methyl aminolevulinate (MAL)
• Topical Medications
  • 5-fluorouracil (5-FU)
  • Imiquimod
  • Ingenolmebutate
  • Diclofenac Sodium
• Chemical Peel and Others

By Geography Segment

• North America (U.S., Rest of North America)
• Europe (U.K., Germany, France, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of Asia Pacific)
• Rest of the World (Middle East & Africa, Latin America)